Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amrutanjan Health CareBOM:590006 -0.70%71 EBITDA Margin % is 7.80% as of Jun. 2026, which is 53% below its 10-year median of 16.67. GuruFocus rates BOM:590006 with a GF Score™ of 71/100 and a GF Value™ of ₹827.69 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Amrutanjan Health Care ranks better than 59.31% on this metric.
Amrutanjan Health Care (BOM:590006) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amrutanjan Health Care EBITDA Margin % Related Terms
Amrutanjan Health Care EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Amrutanjan Health Care's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amrutanjan Health Care (BOM:590006) has a EBITDA Margin % of 7.80% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amrutanjan Health Care and its competitors. This is 53% below median its historical median of 16.67. Over the past decade, Amrutanjan Health Care's EBITDA Margin % has ranged from 14.97 to 25.88. According to the industry distribution chart, Amrutanjan Health Care ranks #391 out of 961 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is Amrutanjan Health Care's EBITDA Margin % too high?
Amrutanjan Health Care's current EBITDA Margin % of 7.80% is 53% below median its 10-year median of 16.67. Over the past 10 years, this metric has ranged from a low of 14.97 to a high of 25.88. The Drug Manufacturers industry median EBITDA Margin % is 11.88. Amrutanjan Health Care's value of 7.80% is 34.3% below this industry median. Based on the distribution chart, Amrutanjan Health Care ranks #391 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #391 out of 961 companies for EBITDA Margin %. This puts Amrutanjan Health Care in the upper half of its industry. The industry median EBITDA Margin % is 11.88. Amrutanjan Health Care's value of 7.80% is 34.3% below this benchmark. Historically, Amrutanjan Health Care's own EBITDA Margin % has ranged from 14.97 to 25.88 over the past decade. While the company's 10-year median is 16.67 vs. the industry median of 11.88, Amrutanjan Health Care has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.88, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amrutanjan Health Care's current EBITDA Margin % of 7.80% is 34.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amrutanjan Health Care and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current EBITDA Margin % is 7.80%, which is 53% below median its own 10-year median of 16.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (BOM:590006) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹827.69, compared to a current price of ₹490.35 — trading 40.8% below its estimated fair value. The current EBITDA Margin % is 7.80%, which is 53% below median its 10-year median of 16.67 and 34.3% below the Drug Manufacturers industry median of 11.88. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amrutanjan Health Care (BOM:590006), the current EBITDA Margin % is 7.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (BOM:590006) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.35 is trading 40.8% below its estimated GF Value™ of ₹827.69.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for BOM:590006:
EBITDA Margin %: 7.80% (53% below median its 10-year median of 16.67)
GF Value™: ₹827.69 vs. price of ₹490.35 (40.8% below fair value)
Industry Position: 34.3% below the Drug Manufacturers median (#391 of 961)
No single metric tells the full story. See the BOM:590006 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for BOM:590006
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:590006 has been successfully added to your 
